ImmunityBio, Inc., a vertically-integrated commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include cytokine fusion proteins, vaccine vectors, and cell therapies. The company's platforms have generated nine first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. The company is based in San Diego, California.

Current Quarter	$-0.08	Next Quarter	$-0.08
Current Year	$-0.4	Next Year	$-0.32
QoQ Growth	+0.0%	YoY Growth	+20.0%
3Y EPS CAGR	+12.8%	Target Price	$10.20
Consensus	Buy	Upside	+332.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IBRX	$2.36	+7.76%	24.74M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IBRX	$2.36	+7.8%	24.74M
3
4
5
6

IBRX

IBRX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get ImmunityBio Inc. Data in Excel

Get ImmunityBio Inc. Data in Excel